• Magn Reson Imaging · Nov 2019

    Diffusion kurtosis imaging does not improve differentiation performance of breast lesions in a short clinical protocol.

    • Theresa Palm, Evelyn Wenkel, Sabine Ohlmeyer, Rolf Janka, Michael Uder, Elisabeth Weiland, Sebastian Bickelhaupt, Mark E Ladd, Maxim Zaitsev, Bernhard Hensel, and Frederik B Laun.
    • Institute of Radiology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Maximiliansplatz 3, 91054 Erlangen, Germany. Electronic address: theresa.palm@uk-erlangen.de.
    • Magn Reson Imaging. 2019 Nov 1; 63: 205-216.

    BackgroundDiffusion weighted magnetic resonance imaging (DWI) is known to differentiate between malignant and benign lesions via the apparent diffusion coefficient (ADC). Here, the value of diffusion kurtosis imaging (DKI) for differentiation and further characterization of benign and malignant breast lesions and their subtypes in a clinically feasible protocol is investigated.Material And MethodsThis study included 85 patients (with 68 malignant and 73 benign lesions) who underwent 3 T breast DWI using three b values (50, 750, 1500 s/mm2), with a total measurement time < 5 min. ADC maps were calculated from b values 50, 750 s/mm2. The diffusion kurtosis model was fitted to the diffusion weighted images, yielding in each lesion the average kurtosis-corrected diffusion coefficient DK and mean kurtosis K. Histopathology was obtained of radiologically suspicious lesions; follow-up scans were used as a standard of reference for benign appearing lesions. Receiver operating characteristic curves were used to evaluate the parameters' diagnostic performance for differentiation of lesion types and grades. The difference in diffusion parameters between subgroups was analysed statistically using the Wilcoxon rank sum test and Kruskal-Wallis test, applying a Bonferroni correction for multiple testing where necessary.ResultsADC, DK and K showed significant differences between malignant and benign lesions (p < 10-5). All parameters had similar areas under the curve (AUC) (ADC: 0.92, DK: 0.91, K: 0.89) for differentiation of malignant and benign lesions. Sensitivity was highest for ADC (ADC: 0.96, DK: 0.94, K: 0.93), as well as specificity (ADC: 0.85, DK: 0.82, K: 0.82). ADC and DK showed significant differences between tumor histologic grades (p = 6.8⋅10-4, p = 6.6 · 10-5, respectively), whereas K did not (p = 0.99). All three parameters differed significantly between subtypes of benign lesions (ADC: p < 10-5, DK: p< 10-5, K: p = 4.1·10-4), but not between subtypes of malignant lesions (ADC: p = 0.21, DK: p = 0.25, K: p = 0.08).ConclusionDKI parameters and conventional ADC can differentiate between malignant and benign lesions. Differentiation performance was best for ADC. Different tumor grades were significantly different in ADC and DK, which may have an impact on therapy planning and monitoring. In our study, K did not add value to the diagnostic performance of DWI in a clinical setting.Copyright © 2019 Elsevier Inc. All rights reserved.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…

What will the 'Medical Journal of You' look like?

Start your free 21 day trial now.

We guarantee your privacy. Your email address will not be shared.